Q-omics provides the consensus-scored ZNF57 profile across patient tissues and cancer cell-line models. ZNF57 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZNF57 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF57 RNA expression shows 19,775 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, KIRC, and ACC as cancer lineages where ZNF57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF57 survival associations across molecular data types. ZNF57 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF57 RNA expression–survival associations across cancer types. High ZNF57 expression shows unfavorable associations in UCS, but favorable associations in UCEC, LUSC, KIRC, HNSC and READ. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for ZNF57 RNA expression.
This table summarizes ZNF57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF57 shows lower tumor expression in KIRC and THCA and higher tumor expression in LIHC, BLCA, LUSC and CHOL. The KIRC box plot shows higher ZNF57 RNA expression in normal versus tumor tissue (log2 FC = −0.665, t-test p < 0.001).
This table shows molecular features associated with ZNF57 in patient tissues and cancer cell lines. In patient samples, ZNF57 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
